MOTS-c (10 mg Vial) Dosage Protocol

MOTS-c (10 mg Vial) Dosage Protocol

#dosing-schedule .dr-container > header { margin-bottom: 0 !important; padding-bottom: 0 !important; }
#dosing-schedule .dr-container > header * { margin-bottom: 0 !important; }
#dosing-schedule .dr-container > header::before, #dosing-schedule .dr-container > header::after { content: none !important; display: none !important; }
#dosing-schedule .dr-container > section:first-of-type { margin-top: 0 !important; display: flow-root; }
#dosing-schedule .dr-container > section:first-of-type h2:first-child { margin-top: 0 !important; }
#dosing-schedule .dr-container .wp-block-spacer, #dosing-schedule .dr-container hr { display: none !important; height: 0 !important; margin: 0 !important; border: 0 !important; }

Quickstart Highlights

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino acid mitochondria-encoded peptide that activates AMPK, improves insulin sensitivity, and mimics many transcriptional effects of aerobic exercise.[1] Plasma levels decline with age and are elevated in centenarian cohorts, suggesting a role in longevity.[2]

  • Reconstitute: Add 2.0 mL bacteriostatic water → 5.0 mg/mL concentration.
  • Research dose: 5–10 mg subcutaneously, 3 times weekly.
  • Easy measuring: At 5.0 mg/mL on a U-100 syringe, 1 unit = 0.01 mL = 50 mcg.
  • Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks.
MOTS-c 10mg Vial

Dosing & Reconstitution Guide

Educational protocol for subcutaneous MOTS-c administration

Research Dosing Protocol (2.0 mL = 5.0 mg/mL)

Phase Dose Units (U-100) Volume Frequency
Starting dose 5 mg 100 units 1.00 mL 3× weekly
Research dose 10 mg 200 units 2.00 mL* 3× weekly

*At the 10 mg dose, the full reconstituted volume is administered in a single injection. Most researchers begin at 5 mg (1.00 mL) to assess tolerability before advancing. A 10 mg vial at 5 mg dose provides 2 injections per vial; at 10 mg, 1 injection per vial. Plan to purchase multiple vials per week for sustained protocols.

Reconstitution Steps

  1. Allow frozen vial to reach room temperature (10–15 minutes).
  2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  3. Inject slowly down the inner vial wall to avoid foaming.
  4. Gently swirl until fully dissolved — do not shake. Solution should be clear and colourless.
  5. Label with reconstitution date; refrigerate at 2–8 °C. Use within 4 weeks.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on a 4-week cycle at 5 mg per injection, 3× weekly (12 injections = 60 mg total).

  • MOTS-c Vials (10 mg each): 60 mg needed ÷ 10 mg per vial → 6 vials.
  • Insulin Syringes (U-100, 1 mL): 12 injections → 12 syringes.
  • Bacteriostatic Water (10 mL bottles): 2.0 mL per vial → 1 × 10 mL bottle per 5 vials.
  • Alcohol Swabs: 2 per injection → 24 swabs per 4-week cycle.
MOTS-c 10mg
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

  • Goal: Improve insulin sensitivity, metabolic flexibility, and exercise capacity via AMPK and folate-AICAR pathway activation.[1]
  • Schedule: Subcutaneous injection 3 times per week (e.g., Mon/Wed/Fri), ideally 30–60 minutes before exercise.
  • Dose range: 5–10 mg per injection.
  • Cycle: 4–12 weeks on, 4 weeks off.
  • Reconstitution: 2.0 mL BAC water per 10 mg vial → 5.0 mg/mL.

Dosing Protocol

  • Starting dose: 5 mg (100 units / 1.00 mL) 3× weekly — assess tolerability for 2 weeks.
  • Research dose: 10 mg (200 units / 2.00 mL) 3× weekly if tolerated.[3]
  • Timing: Morning administration, 30–60 min before exercise, to synergise with the exercise-mimetic effect.
  • Cycle length: 4–12 weeks; 4 weeks off before reassessment.

Storage Instructions

  • Lyophilised: Store at −20 °C (−4 °F); protect from moisture and light.
  • Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
  • Appearance: Clear, colourless solution. Discard if cloudy or particulate.

Important Notes

  • Administer 30–60 minutes before exercise to amplify the metabolic and exercise-mimetic effects.
  • Monitor fasting glucose and energy levels weekly to track metabolic response.
  • At the 10 mg dose, the full 2.0 mL reconstituted volume is administered — split the dose across two sites if needed to improve comfort.
  • Long-term human safety data is not established; follow established peptide handling and storage protocols carefully.

How This Works

MOTS-c is encoded within a short open reading frame (sORF) of the 12S rRNA gene in the human mitochondrial genome, making it a member of the recently discovered class of mitochondrial-derived peptides (MDPs). Discovered by Lee et al. at the University of Southern California in 2015, MOTS-c activates AMPK via the folate-AICAR pathway: it inhibits folate and purine metabolism, causing AICAR accumulation, which in turn activates AMPK independently of AMP/ATP ratios.[1]

Under metabolic stress or exercise, MOTS-c translocates from the cytoplasm into the cell nucleus, where it binds stress-response transcription factors including NRF2 and ATF1 to regulate metabolic gene programmes — directly reproducing many transcriptional signatures of aerobic exercise.[3] Circulating MOTS-c levels decline significantly with age and are elevated in centenarian cohorts.[2]

Potential Benefits & Considerations

  • Insulin sensitivity: Dramatically improved glucose uptake and reduced fat mass in diet-induced obese mice.[1]
  • Longevity association: Centenarians and their offspring have significantly higher plasma MOTS-c than age-matched controls.[2]
  • Exercise mimetic: In aged male mice, exogenous MOTS-c improved grip strength, endurance, and metabolic health independent of voluntary exercise.[3]
  • Safety profile: Animal studies have not reported significant toxicity; long-term human safety data is lacking.
  • Regulatory status: Research peptide — not FDA approved; not on WADA Prohibited List as of 2025.

Lifestyle Factors

  • Pair with regular aerobic exercise to synergise AMPK activation and metabolic benefits.
  • Follow a low-glycaemic, whole-food diet to support insulin sensitivity improvements.
  • Ensure adequate sleep (7–9 hours) — mitochondrial function and metabolic repair are sleep-dependent.
  • Track fasting glucose, body composition, and energy levels to assess research outcomes.

Injection Technique

  • Clean vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully.
  • Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose.
  • Pinch a skin fold; insert needle at 45° into subcutaneous tissue (90° acceptable with short needles into a pinched fold)[CDC].
  • Inject slowly over 2–3 seconds; do not aspirate. Withdraw and apply gentle pressure.
  • Rotate sites (abdomen, thighs, upper arms); dispose of syringe in sharps container immediately.

Important Note

This content is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. This peptide is not approved for human therapeutic use. For research use only.

References


  • Lee C et al. — Cell Metabolism (2015)
    — MOTS-c: a mitochondrial-derived peptide regulating insulin sensitivity via AMPK and the folate-AICAR pathway
    View Source

  • Kim SJ et al. — PNAS (2018)
    — Mitochondria-derived peptides in centenarian cohorts: elevated plasma MOTS-c linked to exceptional human longevity
    View Source

  • Reynolds JC et al. — Nature Communications (2021)
    — MOTS-c translocates to the nucleus during exercise and metabolic stress to directly regulate stress-response gene programmes
    View Source

  • Bachem Peptide Technical Guide
    — Handling and Storage Guidelines for Peptides (lyophilised and reconstituted forms)
    View Source

  • CDC — General Best Practice Guidelines for Immunization
    — Subcutaneous injection technique, angle, and site rotation guidance
    View Source